Full history for every metric is available with a Kvantra account
Applied Genetic Technologies Corporation (AGTC)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 39 | 24 | 42 | 2 | 1 | 0 | 0 |
| Operating profit | $m | -66 | -52 | |||||
| Net profit | $m | 0 | -21 | -2 | -46 | -58 | -71 | -35 |
| EPS reported | $ | -1.59 | -0.81 | |||||
| Operating cashflow per share | $ | -1.46 | -1.46 | |||||
| Capex per share | $ | 0.04 | 0.04 | |||||
| FCF per share | $ | -1.50 | -1.50 | |||||
| Free cash flow | $m | -68 | -52 | |||||
| Net debt | $m | -24 | -18 | |||||
| Book value equity | $m | 29 | 18 | |||||
| Book value per share | $ | 0.65 | 0.39 | |||||
| Number of shares | m | 45.03 | 45.03 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.18 | 1.00 | |||||
| P/S LTM | x | 106.69 | 54.54 | |||||
| P/FCF LTM | x | -0.51 | -0.34 | |||||
| EV/EBITDA LTM | x | -0.17 | 0.00 | |||||
| EV/Sales LTM | x | 33.17 | -0.53 | |||||
| Earnings Yield LTM | % | -205.99% | -402.97% | |||||
| FCF Yield | % | -195.43% | -291.74% | |||||
| Quality | ||||||||
| ROE | % | -242.30% | -123.91% | |||||
| ROIC | % | -127.33% | -127.33% | |||||
| Operating margin | % | -20390.5% | -20390.5% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -20849.8% | -20849.8% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -35.00% | -35.00% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.02 | -2.57 | |||||
| Net Debt/EBITDA | x | 0.37 | 0.37 | |||||
| EBIT/Net interest | x | -24.78 | -24.78 | |||||
| Net debt/market cap | % | -68.91% | -100.97% | |||||
| Net debt/Equity | x | -0.81 | -1.01 | |||||
| Gross debt/equity | x | 0.76 | 1.14 | |||||
Company overview
Applied Genetic Technologies Corporation (AGTC) is a clinical-stage biotechnology company focused on developing innovative genetic therapies aimed at transforming the lives of patients battling rare and debilitating diseases. Its advanced product portfolio includes three ophthalmology development programs addressing two specific targets. These encompass treatments for X-linked retinitis pigmentosa and achromatopsia, both currently undergoing Phase 1/2 clinical trials. Additionally, an optogenetic therapy candidate is in development to tackle advanced retinal conditions. Beyond its ophthalmic initiatives, AGTC is advancing several preclinical programs. These early-stage endeavors include a program for otology (ear disorders), another for dry age-related macular degeneration, and two targeting central nervous system disorders like frontotemporal dementia and amyotrophic lateral sclerosis. The company maintains strategic partnerships with entities such as the University of Florida, Bionic Sight, Inc., and Otonomy, Inc. Founded in 1999, AGTC's operations are based out of its headquarters in Alachua, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Applied Genetic Technologies Corporation (AGTC)
Applied Genetic Technologies Corporation (AGTC) is a clinical-stage biotechnology company focused on developing innovative genetic therapies aimed at transforming the lives of patients battling rare and debilitating diseases. Its advanced product portfolio includes three ophthalmology development programs addressing two specific targets. These encompass treatments for X-linked retinitis pigmentosa and achromatopsia, both currently undergoing Phase 1/2 clinical trials. Additionally, an optogenetic therapy candidate is in development to tackle advanced retinal conditions. Beyond its ophthalmic initiatives, AGTC is advancing several preclinical programs. These early-stage endeavors include a program for otology (ear disorders), another for dry age-related macular degeneration, and two targeting central nervous system disorders like frontotemporal dementia and amyotrophic lateral sclerosis. The company maintains strategic partnerships with entities such as the University of Florida, Bionic Sight, Inc., and Otonomy, Inc. Founded in 1999, AGTC's operations are based out of its headquarters in Alachua, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free